
# Title 21 - Food and Drugs
## Chapter I - Food and Drug Administration, Department of Health and Human Services
### Subchapter F - Biologics
#### PART 600 - BIOLOGICAL PRODUCTS: GENERAL
##### Subpart D - Reporting of Adverse Experiences
###### ยง 600.82 Notification of a permanent discontinuance or an interruption in manufacturing.
####### Noncompliance letters.

(e)If an applicant fails to submit a notification as required under paragraph (a) of this section and in accordance with paragraph (b) of this section, FDA will issue a letter to the applicant informing it of such failure.

(1) Not later than 30 calendar days after the issuance of such a letter, the applicant must submit to FDA a written response setting forth the basis for noncompliance and providing the required notification under paragraph (a) of this section and including the information required under paragraph (c) of this section; and

(2) Not later than 45 calendar days after the issuance of a letter under this paragraph, FDA will make the letter and the applicant's response to the letter public, unless, after review of the applicant's response, FDA determines that the applicant had a reasonable basis for not notifying FDA as required under paragraph (a) of this section.
